• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude Medical rebounds after “Greek tragedy” | Wall Street Beat

St. Jude Medical rebounds after “Greek tragedy” | Wall Street Beat

March 7, 2012 By MassDevice staff

MassDevice.com Wall Street Beat

Shares of St. Jude Medical (NYSE:STJ) clawed back some of the value lost yesterday in what 1 waggish analyst termed a “Greek tragedy.”

STJ shares closed down 3.3% yesterday at $39.96 when the company revealed a $56 million writedown after a Greek distributor failed to pay up for an estimated 2 years worth of sales.

Calling it a "Greek tragedy," Citigroup analyst Matthew Dodds wrote a research note to investors that St. Jude waited longer than other companies to write down its Greek receivables.

"[St. Jude] has not disclosed how long it has been since this distributor has paid them, but our math suggests $56 million is at least 2 years’ worth of sales in Greece based on competitor sales basis (pre-crisis)," Dodds wrote.

The Greek government, the International Monetary Fund and the European Union inked a deal in February to resolve that country’s massive debt crisis.

"This agreement, among other macroeconomic and factors specific to the distributor, negatively impacted the solvency and liquidity of the company’s Greek distributor, raising significant doubt regarding the collectability of our outstanding accounts receivable balance of approximately $56 million," St. Jude said in the SEC filing. "We have also experienced delays in the collectability of receivables in certain European member states, particularly in Southern Europe. Although we still expect to fully collect these receivables, there can be no assurances that additional negative economic disruptions and slowdowns in Europe may result in us not fully collecting these receivables, adversely affecting our cash flows, financial position and results of operations. Additional prolongation of the economic disruptions in Europe may negatively impact reimbursement rates and procedural volumes and adversely affect our business and results of operations."

STJ shares were trading at $40.91 as of about 11:50 today, up 2.4% on the day.

 Nuance to pay $300M to Transcend

Nuance Communications agreed to pay $300 million to acquire medical transcription and speech editing services provider Transcend Services. Read more

 Report: Syneron in talks to buy TransPharma

Syneron Medical (NSDQ:ELOS) is in talks to purchase transdermal drug delivery firm TransPharma Medical for $15 million, according to an Israeli news outlet. Read more

 ACT’s 2011 cash burn ramps up on clinical trials

Advanced Cell Technology (OTC:ACT) said its cash burn went up 55% last year, as it ramped up the first -ever clinical trial involving human embryonic stem cells. Read more

 CareFusion wins $75M DoD contract

CareFusion (NYSE:CFN) won a $75 million contract from the U.S. Defense Dept. for "medical equipment, maintenance and/or spare parts/repair parts of medical equipment. Read more

 Amgen closes Micromet tender offer

Amgen (NSDQ:AMGN) said it now owns more than 88% of Micromet (NSDQ:MITI) and plans to buy the rest by the end of the day, when MITI shares will cease trading publicly and the $11-per-share, $1.16 billion offer closes. Read more

 Allezoe deals Organ Transport Systems back to Healthcare of Today
Allezoe Medical Holdings (OTC:ALZM) agreed to reverse its takeover of Organ Transport Systems from Healthcare of Today Inc. after it realized it will take about $10 million to get the technology ready for market. Read more

 Hill-Rom raises Q2 dividend
Hill-Rom Holdings (NYSE:HRC) raised its 2nd-quarter dividend by 11 percent to 12.5 cents per share, payable March 30. Read more

 Baxter issues Q4 dividend
Baxter International (NYSE:BAX) declared a quarterly dividend of 33.5 cents per share, payable April 2. Read more

 Nordion issues Q4 dividend

Nordion (NYSE:NDZ) declared a quarterly dividend of 10 cents per share, payable April 5. Read more

 Funding Roundup

  • GE Capital loans $15M to BG Medicine
  • Sequent Medical closes $26M Series C round

 Analysts’ ups and downs

  • Baxter (NYSE:BAX): RBC Capital maintains "outperform" rating.
  • Mako Surgical (NSDQ:MAKO): Leerink Swann maintains "market perform" rating, raises price target from $35 to $39.
  • Zeltiq (NSDQ:ZLTQ): Goldman Sachs downgrades from "buy" to "neutral," lowers price target from $19 to $8.50.

Filed Under: News Well, Wall Street Beat Tagged With: Advanced Cell Technology Inc., Allezoe Medical Holdings, Amgen, Baxter, BG Medicine Inc., CareFusion Corp., GE Capital, Hillrom, MAKO Surgical Corp., Micromet, Nordion Inc., Nuance Communications Inc., Sequent Medical, stjudemedical, Syneron Medical Ltd., Transcend Services, TransPharma Medical, Zeltiq

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy